Biologic agents, such as monoclonal antibodies
|
|
- Owen Rich
- 5 years ago
- Views:
Transcription
1 PREDICTING, MEASURING, AND MAINTAINING RESPONSE TO TNF-α ANTAGONISTS IN INFLAMMATORY BOWEL DISEASE Stephen B. Hanauer, MD * ABSTRACT Tumor necrosis factor (TNF) antagonists have substantially improved clinical response and remission rates in patients with Crohn s disease and ulcerative colitis who have not responded adequately to conventional therapies. However, these protein-derived biologic agents are associated with varying degrees of immunogenicity, infusion and injection-site reactions, and loss of treatment response. Clearly, strategies are needed to predict, measure, and maintain response and prevent or restore lost treatment response. This article reviews initial response to treatment with monoclonal antibody-based TNF antagonists, discusses the possible mechanisms for loss of response, and describes strategies to minimize immunogenicity and prevent or restore lost treatment response. The article also addresses the significance of C-reactive protein in the variability of response to therapy, the role of serologic markers and various clinical factors in assessing and monitoring response, and the potential of pharmacogenomics to predict response and enhance drug efficacy and safety. (Adv Stud Med. 2006;6(7E):S750-S759) *Professor of Medicine and Clinical Pharmacology, Chief, Section of Gastroenterology and Nutrition, University of Chicago Hospitals, Chicago, Illinois. Address correspondence to: Stephen B. Hanauer, MD, Chief, Section of Gastroenterology and Nutrition, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 4076, Chicago, IL shanauer@medicine.bsd.uchicago.edu. Biologic agents, such as monoclonal antibodies and antibody fragments targeting tumor necrosis factor-α (TNF-α), have had considerable impact on the treatment of many inflammatory diseases, including Crohn s disease (CD) and ulcerative colitis (UC). For many patients, specifically those with an inadequate response to conventional therapies for inflammatory bowel disease (IBD), treatment with TNF antagonists has produced rapid and substantial improvement in clinical response and remission compared to placebo. 1 However, because these agents are derived from protein molecules and require parenteral administration, they are associated with varying degrees of immunogenicity, infusion and injection-site reactions, and loss of treatment response that call for strategies to predict, measure, and maintain response to these highly efficacious biologic agents. Although there are several available approaches to restoring lost response, strategies to predict response are still emerging. For example, although genetic and serologic testing used for screening and as adjunctive diagnostic techniques in IBD may potentially serve as markers of unique disease course or a predictor of response to specific therapies, to date, neither specific genotypes or serologic markers, such as perinuclear antineutrophil cytoplasmic antibodies (panca) or anti-saccharomyces cerevisiae antibodies, have correlated with response, or lack thereof, to anti-tnf therapies in CD. 2 Eventually, pharmacogenomics may prove to be more useful in this regard, as it involves the multifactorial genetic variations that account for most of the differences in human drug response. 3 S750 Vol. 6 (7E) August 2006
2 RESPONSE TO ANTI-TNF THERAPY INITIAL RESPONSE RATES Before addressing specific strategies and exploring the role of pharmacogenomics, it is worthwhile to review initial response rates to infliximab, which is approved for the treatment of CD and UC, and other TNF antagonists, such as adalimumab and certolizumab pegol, that are being evaluated in phase III trials in patients with CD. Studies evaluating infliximab have shown that it is highly effective in the treatment of luminal and fistulizing CD. In a 4-week, multicenter, double-blind, placebo-controlled, proof-of-concept study in patients with moderate to severe luminal disease that was resistant to conventional therapies, 54 of 83 patients receiving a single infusion of infliximab 5 mg/kg, 10 mg/kg, or 20 mg/kg had a clinical response within 4 weeks versus 4 of 24 patients receiving placebo. 4 Clinical response was defined as a reduction of at least 70 points in the Crohn s Disease Activity Index (CDAI) score. Response rates at 4 weeks were 41% in those receiving infliximab versus 12% in those receiving placebo. In addition, 33% of the patients receiving infliximab went into remission (defined as a CDAI score <150) versus 4% of patients receiving placebo. However, the need for retreatment in patients with luminal CD subsequent to their response to the initial infusion was demonstrated in a study by Rutgeerts et al in which retreatment was shown to maintain response compared to patients who were subsequently randomized to placebo. 5 A subsequent randomized, multicenter, doubleblind, placebo-controlled study in 94 patients with draining abdominal or perianal fistulas of at least 3 months duration demonstrated that intravenous (IV) infliximab 5 mg/kg or 10 mg/kg administered at weeks 0, 2, and 6 was significantly more effective than placebo in reducing the number of draining fistulas by at least 50% from baseline at 2 or more consecutive study visits (primary endpoint) and in promoting closure of all fistulas (secondary endpoint). 6 Of the 31 patients randomized to 5 mg/kg and 32 patients randomized to 10 mg/kg, 68% and 55%, respectively, achieved the primary endpoint versus 26% of the 31 patients randomized to placebo. Rates for achieving the secondary endpoint were 55% in the 5 mg/kg group, 38% in the 10 mg/kg group, and 13% in the placebo group, with fistulas remaining closed for a median of 3 months. In addition, many patients in the study responded before the second or third infusion, suggesting that 3 infusions were not necessary to reduce the number of draining fistulas and promote fistula closure. 1,6 However, the mean duration of response of approximately 12 weeks after all 3 infusions demonstrated that infliximab did not reset the immunostat and that retreatment would be necessary to maintain response and remission. 1 These studies led to 2 randomized trials of maintenance therapy A Crohn s Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT) with ACCENT I involving 573 patients with luminal disease and a CDAI score of at least 220, and ACCENT II involving 306 patients with CD and at least 1 draining abdominal or perianal fistula of at least 3 months duration. 7,8 In ACCENT I, all patients received an IV infusion of infliximab 5 mg/kg at week 0 and were assessed for response at week 2. Those responding to the initial dose with a decrease in the CDAI of 70 points from baseline (58%) were randomized to repeat infusions of placebo at weeks 2 and 6 and every 8 weeks thereafter for 54 weeks (group I, n = 110); repeat infusions of infliximab 5 mg/kg at the same time points (group II, n = 113); or infliximab 5 mg/kg at weeks 2 and 6 followed by 10 mg/kg every 8 weeks (group III, n = 112). The prespecified co-primary endpoints of the trial were the proportion of patients who responded at week 2 and were in remission (CDAI <150) at week 30, and the time to loss of response. 7 (Mechanisms accounting for loss of response and strategies to prevent or restore lost response are discussed in greater detail in the Loss of Response section of this article.) At week 30, significantly more patients in groups II (39%) and III (45%) were in remission compared with group I (21%). Median time to loss of response was 38 weeks in group II and more than 54 weeks in group III compared to 19 weeks in group I. In addition, patients in groups II and III were more likely to maintain response and remissions while discontinuing corticosteroid therapy. 7 In ACCENT II, patients with refractory fistulizing CD received a series of 3 infusions of infliximab 5 mg/kg at weeks 0, 2, and 6. A total of 282 patients 195 who responded at weeks 10 and 14 and 87 who had no response were then randomized to infliximab 5 mg/kg every 8 weeks or placebo and followed for 54 weeks. The primary endpoint was time to loss of Johns Hopkins Advanced Studies in Medicine S751
3 response (reduction of 50% in the number of draining fistulas) among patients who responded at week 14 and underwent randomization. 8 At week 54, 36% of patients receiving infliximab had no draining fistulas compared to 19% of patients receiving placebo. Time to loss of response was significantly longer in the patients receiving infliximab than in those receiving placebo (>40 weeks vs 14 weeks; P <.001). 8 All of the infliximab trials described above demonstrated that maintenance therapy is necessary in most patients with CD and that regularly scheduled therapy is more beneficial than episodic as needed treatment. 1 The latter was confirmed in another analysis of the ACCENT I study that directly compared scheduled and episodic treatment strategies. 9 The study found that scheduled treatment resulted in better CDAI responses, higher response and remission rates, higher rates of mucosal healing, fewer hospitalizations, and less immunogenicity with no increase in adverse side effects. Studies of other TNF antagonists have shown that they too are effective in inducing response and remission in patients with CD. In a multicenter, randomized, placebo-controlled, dose-ranging study evaluating adalimumab in 299 patients with moderately to severely active CD and no prior exposure to TNF antagonists, 30% of patients receiving the 2 higher (of 3) doses of the drug at weeks 0 and 2 achieved clinical remission at 4 weeks versus 12% of patients receiving placebo. 10 Results were not dependent on baseline concentrations of C-reactive protein (CRP). In this study, subcutaneous (SC) doses of adalimumab were 160 mg at baseline and 80 mg at week 2 (160 mg/80 mg), 80 mg/40 mg, and 40 mg/20 mg. Clinical remission was defined as a CDAI score of lower than 150, and clinical response was defined as a reduction in CDAI score from baseline of 70 or more or 100 or more points. Response rates among patients receiving the 160 mg/80 mg and 80 mg/40 mg doses were 56.5% for a reduction of 70 or more points (vs 35% in the placebo group) and 43% for a reduction of 100 or more points (vs 23% in the placebo group). 10 A randomized, placebo-controlled trial evaluating 3 different doses of the TNF antagonist certolizumab pegol (CDP870) in 292 patients with moderate to severe CD found that clinical response and remission rates at 12 weeks were significantly higher in patients with elevated CRP levels who received the highest dose (400 mg SC at weeks 0, 4, and 8) than in those receiving placebo (53% vs 18%; P =.005). 11 Rates for all doses in the group as a whole were higher than those seen with placebo, but the differences were not statistically significant. However, preliminary results from a 26-week, phase III trial have shown that certolizumab pegol was effective in inducing and maintaining response and remission in patients with moderate to severe CD regardless of CRP levels. 12 ATTENUATED RESPONSE Despite good initial response rates to anti-tnf agents, some patients with CD lose their response or have an attenuated response to therapy, and at least 33% who receive this therapy fail to show any useful response. 13 However, studies have shown that patients with attenuated or lost response to infliximab may respond to treatment with other antibody-derived TNF agents. In a study of 15 patients with active CD who had an attenuated response to infliximab, 7 patients had a complete response to adalimumab over a 6-month period, 4 had a partial response, 2 had no response, and 2 had inadequate follow-up. 14 In another uncontrolled pilot study of adalimumab in 24 patients with CD who had a good initial response to infliximab but lost response over time or experienced acute or delayed infusion reactions, the investigators found that adalimumab produced a complete response in 5 patients and a partial response that was enhanced by dose escalation during maintenance therapy in 19 patients. 15 All 24 patients were able to tolerate adalimumab. When these results are considered with similar findings from another pilot study evaluating the TNF antagonist CDP571 in 20 patients who had acute or delayed infusion reactions to infliximab, 16 it is reasonable to conclude that patients who experience acute or delayed infusion reactions to infliximab can be safely retreated with other anti-tnf agents. 17 Similar results regarding retreatment with other anti-tnf agents have been reported in patients with rheumatoid arthritis who experienced infusion reactions to infliximab. 18 Efficacy data from another open-label pilot study evaluating adalimumab in patients with prior loss of response to infliximab have shown that 59% had a clinical response (ie, a reduction in CDAI score of 100 points) at 12 weeks, 29% were in clinical remission (CDAI <150), and 56% with draining fistulas at baseline had reduced the number of draining fistulas by at least 50%. 19 S752 Vol. 6 (7E) August 2006
4 LOSS OF RESPONSE As noted earlier in this article, some patients lose responsiveness to infliximab over time or become intolerant to the drug. The major reasons for loss of response are: the development of antibodies to the drug, which increases the risk of infusion reactions; differences in acquired resistance to anti-tnf agents; and the development of noninflammatory signs and symptoms, such as bowel strictures, short bowel, or irritable bowel syndrome. 20,21 IMMUNOGENICITY All biologic agents, whether chimeric, humanized, or fully human, have the potential to be antigenic (ie, the ability of a molecule to be recognized by a pre-existing B- or T-cell receptor), immunogenic (development of an immune response), or tolerogenic (development of tolerance), depending on mode of administration, uptake by and costimulation of antigen-processing cells, and exogenous factors such as concomitant immunesuppressing therapies. Interpretation of immunogenicity may be complicated by different assay formats with differing sensitivities and cut-offs, different biologic epitopes, and interference of assay systems in the presence of the antigenic protein. Factors that increase immunogenicity include IV administration, low-dose exposure, and episodic administration. Immunogenicity can be reduced by SC administration, high-dose induction therapy, scheduled maintenance treatment, and administration with concomitant immune suppression. Ultimately, immunogenicity can be determined by the measurement of antibiologic antibodies, by measurement of concentrations of biologics, or by measurement of concentrations of TNF-α. 22 Although all of the anti-tnf biologic agents have the potential to induce immunogenicity, there are more data on immunogenicity to infliximab because the drug has been available for the past 8 years. Several studies have shown that infliximab is immunogenic, leading to the formation of human antichimeric antibodies, also known as antibodies to infliximab (ATI), in patients with CD, rheumatoid arthritis, and ankylosing spondylitis. 4-8,20,21,23,24 Some of these studies and others have investigated the incidence and pharmacokinetics of ATI, the impact of ATI on long-term efficacy and relationship to adverse effects, and strategies to reduce ATI formation. 7,8,20,23,25-27 Data regarding immunogenicity to adalimumab and certolizumab pegol have been less forthcoming. 28 In rheumatology trials, antibodies to adalimumab appear in approximately 6% of patients and are reduced by coadministration of methotrexate. 29 Infliximab immunogenicity The lower incidence of ATI in patients receiving concomitant immunomodulatory therapy was clearly demonstrated in ACCENT I, ACCENT II, and a study by Baert et al. 7,8,20 In ACCENT I, the overall incidence of ATI was 28% in patients receiving episodic treatment (ie, group I, which received a single infliximab dose at week 0 and placebo infusions at weeks 2 and 6 and every 8 weeks thereafter), 9.1% in group II, and 6.3% in group III. 30 However, the incidence of ATI was lower in patients in all 3 groups who received concomitant therapy with immunomodulators (Figure 1). 23 In ACCENT II, the incidence of ATI was 24% in patients who received no concomitant medications at baseline, 13% in patients who received steroids, 11% in those who received immunomodulators, and 3.7% in those who received both. 30 In a study conducted by Baert et al in 125 consecutive patients with CD who received 1 to 17 (mean, 3.9) infliximab infusions episodically over 10 months, the overall incidence of ATI was 61%. 20 When immunomodulator was considered, a significantly lower proportion of patients receiving these drugs were ATI positive compared to patients who were not receiving them (43% vs 75%; P <.01). Figure 1. Incidence of ATI with and without Immunomodulators in ACCENT I Proportion of patients, % Episodic strategy 11 7 Maintenance q 8 wk 5 mg/kg No immunomodulators With immunomodulators 8 4 Maintenance q 8 wk 10 mg/kg ACCENT = A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long- Term Treatment Regimen; ATI = antibodies to infliximab. Reprinted with permission from Hanauer et al. Clin Gastroenterol Hepatol. 2004;2: Johns Hopkins Advanced Studies in Medicine S753
5 Figure 2. Impact of ATI on Infliximab Concentrations, Infusion Reactions, and Loss of Response Antibodies associated with infusion reaction Infusion reactions with decreased infliximab levels - Inf Rx + Inf Rx ATI with short duration of response 0 ATI Level Infliximab Level Time to Next Week 0 Week 4 Infusion, wks ATI = antibodies to infliximab; Inf = infusion; Rx = reaction. Reprinted with permission from Baert et al. N Engl J Med. 2003;348: Clinical impact of ATI The study of Baert et al also evaluated concentrations of infliximab and ATI, in addition to the impact of ATI on infusion reactions and loss of response. 20 As shown in Figure 2, ATI reduce serum infliximab levels, increase the risk of infusion reactions, and reduce the duration of response to treatment. ATI concentrations 80 µg/ml or more before an infusion predicted a significantly shorter duration of response 35 days versus 71 days among patients with concentrations 80 µg/ml or less (P <.001) and a 24-fold increased risk of infusion reactions (P <.001). Infliximab concentrations were also significantly lower at 4 weeks among patients who had an infusion reaction than among those who did not (P <.001). In addition, infusion reactions were associated with significantly shorter duration of clinical response. The median duration of clinical response in patients who had infusion reactions was 38.5 days versus 65 days among those who did not have an infusion reaction (P <.001). 20 In another study investigating the impact of ATI on clinical response, Farrell et al found that 68% of 53 patients treated with 199 infusions of infliximab 5 mg/kg responded to initial therapy, but that 42% of them lost response. 27 Of the 15 patients who lost their initial response, 11 were positive for ATI, including all 7 who also had serious infusion reactions. ATI developed in 36% of the group as a whole. However, 86% of patients who did not have ATI responded to retreatment versus 48% of those who were ATI positive. Patients were retreated with a second infliximab infusion within 8 weeks of the first infusion or concurrent immunosuppressants; both strategies significantly reduced ATI formation. The study investigators subsequently evaluated the effects of IV hydrocortisone premedication versus placebo on ATI levels in 80 patients. 27 They found that pretreatment with IV hydrocortisone significantly reduced ATI levels compared to placebo, but that it did not eliminate ATI formation or infusion reactions. Minimizing the impact of ATI Data from trials evaluating infliximab in CD have suggested several strategies to minimize the clinical impact of ATI (Figure 3). However, additional strategies need to be considered when there is loss of response to therapy. First, it is worth noting that loss of response is not always due to ATI. It may result from noninflammatory signs and symptoms, such as bowel strictures or from acquired resistance to anti-tnf agents. 21 Therefore, it is crucial to reassess patients for inflammatory signs and symptoms, with laboratory tests for CRP levels, colonoscopy, and radiologic procedures, to confirm that active disease is present. If reassessment confirms that active inflammation is present, then ATI need to be evaluated further, as summarized in Figure 4. Several studies have shown that using other TNF antagonists, such as adalimumab and certolizumab pegol, is a viable alternative in patients with CD with prior loss of response to infliximab. 11,12,15,19 These agents appear to be less immunogenic than infliximab, 31 and results thus far have been promising. However, as is the case in patients with rheumatoid arthritis, patients with CD often respond to alternative anti-tnf antibodies or antibody fragments after loss of response to an initial biologic agent, but the results are not quite as good with the second agent. The best overall approach at present is to use the dose optimization strategies outlined in Figure 3 rather than immunize patients to infliximab with the most immunogenic regimen (ie, a single dose of the drug without immunomodulating therapy, followed by episodic or as needed dosing). 31 These strategies are based on the best available evidence from observational studies. 31 S754 Vol. 6 (7E) August 2006
6 Another approach to preventing immunization is to utilize concomitant immune suppression with methotrexate, a thiopurine antimetabolite, or pretreatment with high-dose corticosteroids. 28,32,33 ROLE OF PHARMACOGENOMICS Pharmacogenomics is an extension of pharmacogenetics, a science rooted in a number of clinical observations that predicted genetic alterations of drug response. 3 Additional case discoveries and systematic case studies led to the recognition of systematic pharmacogenetic differences between human populations and the realization that most drug-response differences in humans were multifactorial, resulting from numerous genetic alterations plus environmental factors. 3 Recognition of these Figure 3. Strategies to Minimize ATI Impact 3-dose induction regimen (infliximab 5 mg/kg) to maximize efficacy/tolerance AND Scheduled maintenance regimen (every 8 weeks) to increase duration of response AND/OR Concurrent immunomodulators to reduce ATI AND/OR Pretreatment with high-dose corticosteroids ATI = antibodies to infliximab. Figure 4. Assessing Loss of Response Antibodies to infliximab (+) (-, no infliximab) (-, infliximab present) Alternative Reduce infusion Alternative target anti-tnf interval or agent increase dose to 10 mg/kg TNF = tumor necrosis factor. complexities, along with the advance of genetics into genomics, led to the broader science of pharmacogenomics, 3 which studies the genetic polymorphisms that underlie the variability in drug response between individuals and the relationship between drug effects and the genome. 34,35 As such, pharmacogenomics has the potential to create personalized medicine (ie, making drugs safer and more effective through their action on genetic variants so that the drugs fit the individual s genes) and to develop DNA-based tests to maximize drug efficacy and enhance drug safety. 3,36 Two branches of pharmacogenomics have emerged: structural pharamacogenomics, which maps the DNA sequence of whole genomes (genotypes), including genetic variations; and functional pharmacogenomics, which can simultaneously assess the levels of expression of thousands of genes. 35 Together, both branches have generated massive databases that may substantially improve the drug development process with regard to identifying drug targets, evaluating toxicity, classifying diseases, evaluating drug formulations, assessing drug responses and treatment, and developing personalized medicines. However, much more clinical and translational research is needed, particularly in the latter area. At present, personalized medicine is best represented by a physician s attention to patient population factors that indicate less genetic variation than is typical of the general population (ie, a patient s age, gender, race, and ethnicity). 37 However, there has been some progress in using genomic techniques to predict which patients with CD will respond to anti- TNF or immunomodulator therapy and which patients will not. 13,38-41 In a review article, Shetty and Forbes noted that the need to predict response to anti-tnf therapy and anticipated relapse was extremely important because at least 33% of patients with CD who are candidates for therapy with TNF antagonists fail to show any useful response. 13 With the need to identify predictive factors in mind, the investigators noted several TNF polymorphisms in CD and UC that were possibly associated with poor response to infliximab, including increasing mucosal levels of activated nuclear factor kappa B, a pro-inflammatory transcription factor; homozygosity for the polymorphism in exon 6 of TNF receptor 2 (genotype Arg196Arg); positivity for panca; and the presence of increased numbers of activated mononuclear cells in the lamina propria producing interferon-γ and TNF-α. Johns Hopkins Advanced Studies in Medicine S755
7 In contrast, the authors of another review article noted that polymorphisms in TNF receptor 1 and TNF receptor 2 were not associated with treatment response. 38 They also found no association between treatment response and the 3 mutations in the CARD15 gene that are independently associated with susceptibility to CD. Characterizing the development of anti-tnf agents as a simple and logical molecular strategy with complex clinical consequences, Waetzig and Schreiber reviewed the mechanisms by which infliximab inhibits the production of TNF-α. 39 However, in their discussion of the variability of response among patients treated with the drug, they concluded that response to TNF antagonists was not determined by polymorphisms in the TNF, TNF receptor, or NOD2 genes, but may be determined by variations in other genes in or outside the TNF signaling cascade. In a review article describing the genetic variants that influence the efficacy or toxicity of infliximab and other drugs commonly used to treat IBD, Pierik et al noted that there was no difference in treatment response, as measured by CDAI, in patients with CD receiving infliximab who were genotyped for R702W, G908R, and 1007InsC in CARD There were also no significant associations between treatment response and single nucleotide polymorphisms (SNPs) in the main target molecule of TNF-α (-238, -308, -376, -857, -1031) and its receptors (-609 and +36 or P12P in TNF receptor 1 and 168 or L56L, 587 M196A, 1663, and 1690 in TNF receptor 2). However, because the efficacy of infliximab in CD is partially due to the drug s ability to induce apoptosis of activated T lymphocytes, it was thought that investigations of the effect of polymorphisms in apoptosis genes in patients with luminal or fistulizing CD would yield valuable data with regard to predicting response to infliximab therapy. 40 One such study, involving a cohort of 287 patients treated with infliximab for luminal or fistulizing CD, found that 74.7% of patients carrying the Fas ligand -843 CC/CT genotypes responded to therapy compared to 38.1% of those with the TT genotype. 41 In the same cohort, all patients with the caspase 9 93 TT genotype responded to therapy compared to 66.7% of patients with the CC and CT genotypes. A separate study investigating the association between the FCGR3A-158 polymorphism (expressed in macrophages and natural killer cells) and response to infliximab in 142 patients with refractory luminal CD and 58 patients with fistulizing CD found that 82.9% of those with the VV genotype and 72.7% of those with VF or FF genotypes had a clinical response to the drug, as measured by CDAI. 42 In addition, all patients with the VV genotype had a biological response to infliximab, defined as a decrease in CRP of at least 25% from baseline, versus 69.8% of patients with 1 or more F alleles. These findings suggest that patients with CD with the FCGR3A-158 VV genotype have a better biological response, and possibly a better clinical response, to infliximab. In another review article, Egan et al pointed out that clinically significant genetic variations consist of SNPs within genes that affect drug disposition and drug targets. 43 Although relatively few clinically important examples of inherited traits that affect drug responses have been studied in detail thus far, the pharmacogenetics of thiopurine methyltransferase have been studied and are highly relevant to the response to azathioprine/6-mercaptopurine in patients with CD or UC. Those patients with 2 normal alleles of the gene encoding thiopurine methyltransferase metabolize and clear thiopurines such as azathioprine/6-mercaptopurine rapidly, whereas those with 2 variant alleles of the gene clear them very slowly, and those with 1 normal and 1 variant allele are intermediate. Slow and intermediate metabolizers are predisposed to high active thiopurine levels and are at higher risk for developing bone marrow suppression. The authors also noted that the use of highthroughput SNP genotyping and careful phenotypic characterization of CD and UC enhanced the potential of pharmacogenomics to identify individual biomarkers that predict the relative likelihood of benefit or risk from a therapeutic intervention. 43 STRATEGIES TO MONITOR PATIENTS FOR IMMUNOGENICITY AND OTHER TOXICITIES Because therapeutic proteins, such as infliximab, are associated with the formation of antibodies, which increase the risk of serious adverse reactions and infections and lead to loss of response, it is essential to assess patients for continued response and monitor patients for the development of antibodies and adverse events during induction and primarily S756 Vol. 6 (7E) August 2006
8 during maintenance therapy. One gauge that can be used to assess and monitor anti-tnf therapy is the need for dose escalation of the TNF antagonist and intensification of cotherapy over time. A study of nearly 1200 patients with rheumatoid arthritis (representing 1450 patient-years of anti- TNF treatment) found that those treated with infliximab were more likely to have a reduced therapeutic response after the first 6 months of treatment and were more likely to require intensification of cotherapy with disease-modifying antirheumatic drugs than patients receiving etanercept or adalimumab. 21 The study investigators noted that the reduced therapeutic response to infliximab over 6 months was suggestive of acquired drug resistance. Although the study involved patients with rheumatoid arthritis, the findings are also applicable to the assessment of response in patients with CD. In addition, a general proviso should be that clinicians remain vigilant with regard to the occurrence of serious events, such as serum sickness-like reaction, opportunistic infections and sepsis, and autoimmune disorders. 44 Reports associating anti- TNF therapy with an increased risk of opportunistic infections, particularly tuberculosis and other intracellular pathogens, have raised concerns and prompted the US Food and Drug Administration to recommend tuberculin skin testing in all candidates for infliximab therapy. 28,45,46 However, a study of 70 patients with CD and 12 patients with other inflammatory bowel conditions found that none of them had a positive response to skin tests administered before or between infliximab infusions. 46 Moreover, a significantly higher proportion of patients who also received corticosteroids and/or immunomodulators for at least 1 month were anergic compared to those who did not receive these drugs (83% vs 43%; P <.002). Given the high prevalence of anergy, the study investigators concluded that a negative tuberculin skin test alone was an unreliable indicator of exposure to tuberculosis. 46 They recommended a more thorough evaluation of tuberculosis risk in patients being considered for infliximab therapy, including a skin test, a detailed history of travel, other exposure to tuberculosis, and symptoms such as chronic cough and weight loss, and a chest X ray. In addition, the use of the QuantiFERON (Cellestis Limited, Carnegie, Victoria, Australia) assay may identify patients at risk for reactivation of tuberculosis in the setting of anergy or previous immunization with bacillus Calmette-Guérin. CONCLUSIONS Studies have shown that infliximab, thus far the only TNF antagonist approved for the treatment of CD, is highly effective in treating the luminal and fistulizing forms of the disease. However, other investigations have shown that many patients treated with TNF antagonists lose their response over time and that at least 33% fail to show any clinically meaningful response. Immunogenicity (ie, the formation of antibodies to TNF antagonists) is the major reason for loss of response and adverse infusion reactions, although differences in acquired drug resistance to these agents and the development of noninflammatory signs and symptoms, such as bowel strictures, also play a role. Strategies to minimize the impact of antibody formation, particularly to infliximab, include a 3-dose induction regimen, a scheduled maintenance regimen, the concurrent use of immunomodulators, and pretreatment with high-dose corticosteroids. The use of other TNF antagonists, such as adalimumab and certolizumab pegol, which appear to be less immunogenic than infliximab and have been shown to be effective in patients with prior loss of response to infliximab, is another alternative. Both of these agents are currently being evaluated in phase III trials involving patients with CD. Although all TNF antagonists target TNF, there is considerable variability in response to these agents among patients. The science of pharmacogenomics, which studies the genetic polymorphisms that underlie the variability in drug response between individuals, has the potential to make drugs safer and more effective through their action on genetic variants so that the drugs fit the individual s genes. It is essential to assess and monitor patients for the development of antibodies and adverse events during induction and maintenance therapy. Clinicians should consider patient factors that indicate reduced genetic variations (ie, age, gender, and race) in assessing and predicting patient response to therapy, and they should remain vigilant with regard to the development of antibodies and the occurrence of serious adverse events. Johns Hopkins Advanced Studies in Medicine S757
9 REFERENCES 1. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn s disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004;4(suppl 3):S18-S Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004;4: Kalow W. Pharmacogenomics: historical perspective and current status. Methods Mol Biol. 2005;311: Targan SR, Hanauer SB, van Deventer SJ, et al. A shortterm study of chimeric monoclonal antibody ca2 to tumor necrosis factor alpha for Crohn s disease. Crohn s Disease ca2 Study Group. N Engl J Med. 1997;337: Rutgeerts P, D Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn s disease. Gastroenterology. 1999;117: Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn s disease. N Engl J Med. 1999;340: Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn s disease: the ACCENT I randomised trial. Lancet. 2002;359: Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn s disease. N Engl J Med. 2004;350: Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn s disease. Gastroenterology. 2004;126: Hanauer S, Lukáš M, MacIntosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-tnf-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn s disease. Gastroenterology. 2004;127: Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn s disease. Gastroenterology. 2005;129: Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanised anti-tnf PEGylated Fab1 fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn s disease: a phase III study (PRECiSE). Presented at: 13th United European Gastroenterology Week; October 18, 2005; Copenhagen, Denmark. 13. Shetty A, Forbes A. Pharmacogenomics of response to antitumor necrosis factor therapy in patients with Crohn s disease. Am J Pharmacogenomics. 2002;2: Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn s disease in patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100: Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn s disease. Gastroenterology. 2004;126:A53-A Hanauer S, Present D, Targan SR, et al. CDP571, a humanized monoclonal antibody to TNF-α, is well tolerated in Crohn s disease patients with previous hypersensitivity in infliximab. Gastroenterology. 2003;124:A Sandborn WJ. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn s disease. Rev Gastroenterol Disord. 2004;4(suppl 3):S25-S Solau-Gervais E, Laxenaire N, Cortet B, et al. Lack of efficacy of a third tumour necrosis factor {alpha} antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford). 2006; [Epub ahead of print]. 19. Sandborn WJ, Hanauer SB, Loftus EV, et al. An open-label study of the human anti-tnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn s disease. Am J Gastroenterol. 2004;99: Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn s disease. N Engl J Med. 2003;348: Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65: Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn s disease. Clin Immunol. 2006;118: Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn s disease. Clin Gastroenterol Hepatol. 2004;2: Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int. 2006;26: Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn s disease treated with chimeric monoclonal anti-tnf alpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003;15: Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn s disease: a prospective cohort study. Gastroenterology. 2003;125: Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn s disease: a randomized controlled trial. Gastroenterology. 2003;124: Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22: Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34(suppl 1): Data on file. Centocor, Inc.; Horsham, Pa. 31. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn s disease: optimize not immunize. Gastroenterology. 2003;124: S758 Vol. 6 (7E) August 2006
10 32. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn s disease. Drugs. 2004;64: Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease seven years on. Aliment Pharmacol Ther. 2006;23: Mahlknecht U, Voelter-Mahlknecht S. Pharmacogenomics: questions and concerns. Curr Med Res Opin. 2005;21: Regnstrom K, Burgess DJ. Pharmacogenomics and its potential impact on drug and formulation development. Crit Rev Ther Drug Carrier Syst. 2005;22: Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005;4: Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6: Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-tnf therapy in patients with Crohn's disease. Pharmacogenomics. 2004;5: Waetzig GH, Schreiber S. Mechanisms of infliximab. The reverse side of a drug effect. Inflamm Bowel Dis. 2004;10(suppl 1):S38-S Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory disease. World J Gastroenterol. 2006;12: Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005;22: Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004;19: Egan LJ, Derijks LJ, Hommes DW. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4: Columbel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126: Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27: Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PDD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2: Johns Hopkins Advanced Studies in Medicine S759
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationSubmitted by xxxxxxxxxxxxxxxxx, xxxxxxxxx RCP and co-ordinated by xxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxx, Royal Liverpool University Hospital.
Royal College of Physicians statement on the appraisal of use of tumour necrosis factor alpha (TNF-α) inhibitors (adalimumab, certolizumab pegol and infliximab) and natalizumab for Crohn's disease Submitted
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationBEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE. Stephen B. Hanauer, MD*
BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE Stephen B. Hanauer, MD* ABSTRACT *Professor of Medicine and Clinical Pharmacology; Chief, Section of Gastroenterology,
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn s Disease
The new england journal of medicine original article Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn s Disease Filip Baert, M.D., Maja Noman, M.D., Severine Vermeire, M.D.,
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationAssociation of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn s Disease
CLINICL GSTROENTEROLOGY ND HEPTOLOGY 26;4:1248 1254 ssociation of Trough Serum Infliximab to Clinical Outcome fter Scheduled Maintenance Treatment for Crohn s Disease ELN. MSER, RENT VILLEL, MRK S. SILVERERG,
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationIntravenous Hydrocortisone Premedication Reduces Antibodies to Infliximab in Crohn s Disease: A Randomized Controlled Trial
GASTROENTEROLOGY 2003;124:917 924 Intravenous Hydrocortisone Premedication Reduces Antibodies to Infliximab in Crohn s Disease: A Randomized Controlled Trial RICHARD J. FARRELL, MAZEN ALSAHLI, YOON TAE
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationGastroenterology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, USA.
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Infliximab: A Review of its Use in the Treatment of Crohn s Disease
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationCorporate Medical Policy
Corporate Medical Policy Measurement of Serum Antibodies to Infliximab, Adalimumab and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_serum_antibodies_to_infliximab_and_adalimumab
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationBiologic therapy with antagonists to tumor necrosis factor
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:696 702 Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn s Disease: Results From the PRECiSE 4 Study WILLIAM J. SANDBORN,* STEFAN SCHREIBER,
More informationTargeting nanomedicines in the treatment of Crohn s disease: focus on certolizumab pegol (CDP870)
REVIEW Targeting nanomedicines in the treatment of Crohn s disease: focus on certolizumab pegol (CDP870) Lotte Dinesen Simon Travis Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK Abstract:
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationManuela Marzo, Carla Felice, Gian Lodovico Rapaccini, Luisa Guidi and Alessandro Armuzzi
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Infliximab: A Review of Its Use in the Treatment of Inflammatory
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationEffect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series
CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationClinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
nature publishing group ORIGINAL CONTRIBUTIONS 1133 see related editorial on page 1140 Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationThe advent of infliximab (Remicade; Centocor, Optimizing Anti-TNF Treatment in Inflammatory Bowel Disease
GASTROENTEROLOGY 2004;126:1593 1610 Optimizing Anti-TNF Treatment in Inflammatory Bowel Disease PAUL RUTGEERTS, GERT VAN ASSCHE, and SÉVERINE VERMEIRE Department of Medicine, Division of Gastroenterology,
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationPREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY
Gut Online First, published on August 19, 2005 as 10.1136/gut.2005.076034 PREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY DS Rampton Centre for Gastroenterology,
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationPACKAGE INSERT. Each vial of the REVELLEX product contains 100 mg of infliximab. After reconstitution, each vial
PACKAGE INSERT SCHEDULING STATUS S4 PROPRIETARY NAME AND DOSAGE FORM REVELLEX 100 mg COMPOSITION Each vial of the REVELLEX product contains 100 mg of infliximab. After reconstitution, each vial of REVELLEX
More informationAssessing Response and Loss of Response to Biological Therapies in IBD
CLINICAL AND SYSTEMATIC S nature publishing group 685 Assessing Response and Loss of Response to Biological Therapies in IBD Henit Yanai, MD 1 and Ste phe n B. Hanau e r, M D 2 OBJECTIVES: METHODS: RESULTS:
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationClinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Gut and Liver, Published online September 9, 2016 ORiginal Article Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease So Yoon
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationUtility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i17.5031 World J Gastroenterol 2014 May 7; 20(17): 5031-5035 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationAdvances in the development of new biologics in inflammatory bowel disease
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-6 Advances in the development of new biologics in inflammatory bowel disease Bella Ungar, Uri Kopylov Sheba Medical Center, Tel Hashomer and Sackler
More informationAdvances in Management of Inflammatory Bowel Disease: The Biological Therapies Era
Advances in Management of Inflammatory Bowel Disease: The Biological Therapies Era Subrata Ghosh*, Rakesh Chaudhary** *Chair in Gastroenterology, **Clinical Research Fellow,Gastrointestinal Section, Imperial
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationInfliximab Therapy in Pediatric Patients 7 Years of Age and Younger
ORIGINAL ARTICLE: GASTROENTEROLOGY Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger Judith R. Kelsen, Andrew B. Grossman, Helen Pauly-Hubbard, Kernika Gupta, Robert N. Baldassano, and
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Serum Antibodies to Infliximab Page 1 of 8 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Serum Antibodies to Infliximab Professional
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationBiological Therapy for Inflammatory Bowel Disease in Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/kjpgn.2012.15.1.13 Pediatric Gastroenterology, Hepatology & Nutrition 2012 March 15(1):13-18 Review Article PGHN Biological Therapy for Inflammatory
More informationSynopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationThe evaluation and treatment of patients with Crohn s
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:395 399 PERSPECTIVE Do Not Assume Symptoms Indicate Failure of Anti Tumor Necrosis Factor Therapy in Crohn s Disease DAVID H. BRUINING* and WILLIAM J. SANDBORN
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More information